Loading organizations...
Macrophage Pharma is a technology company.
Macrophage Pharma develops targeted therapeutics utilizing its proprietary Effector Selective Macrophage (ESM™) technology platform. This platform delivers small molecule drugs directly to tumor-associated macrophages, selectively modulating their activity. The company focuses on re-educating these immune cells to enhance anti-tumor responses and address inflammation.
Founded in 2015 by David Moffat, Macrophage Pharma emerged from the CRT Pioneer Fund. The foundational insight centered on the critical, often immunosuppressive, role of macrophages within the tumor microenvironment. By precisely targeting these specific cells, the company aimed to harness the body's natural immune system for therapeutic benefit.
The product aims to benefit patients with cancer and inflammatory diseases. Macrophage Pharma's long-term vision involved advancing novel immunotherapies to address unmet medical needs. The company sought to pioneer a new class of drugs that precisely control macrophage function, offering more effective and less toxic treatment options for challenging conditions.
Macrophage Pharma has raised $11.0M across 1 funding round.
Macrophage Pharma has raised $11.0M in total across 1 funding round.
Macrophage Pharma has raised $11.0M in total across 1 funding round.
Macrophage Pharma's investors include CRT Pioneer Fund, M Ventures (Merck), Aglaia, Novo Seeds.
Macrophage Pharma is a UK-based immuno-oncology biotechnology company developing novel small molecule therapies that selectively target macrophages to enhance anti-tumor immune responses.[1][2][5] Its proprietary Esterase Sensitive Motif (ESM™) technology platform delivers drugs to tumor-associated macrophages, activating the body's immune system against cancer, with its lead candidate being a macrophage-targeted p38 MAPK inhibitor advancing toward clinical trials.[1][2] The company serves oncology patients by addressing unmet needs in modulating the tumor microenvironment, solving the problem of immunosuppressive macrophages that hinder immunotherapy efficacy, and raised £9 million in Series A financing in 2017 to fund preclinical and early clinical development, including pipeline expansion.[1][2]
Macrophage Pharma was founded in 2016 by the CRT Pioneer Fund (CPF), a specialist investor in early-stage oncology ventures, and is headquartered in Windsor, United Kingdom.[2][4][5] The company emerged from acquiring global rights to the ESM™ platform and discovery assets from Chroma Therapeutics, enabling rapid startup with a validated technology for macrophage targeting.[2] Early traction came via a £9 million Series A round led by CPF, with participation from Novo Seeds (part of Novo Holdings) and Aglaia Biomedical Ventures, funding preclinical advancement of its p38MAP kinase inhibitor (clinical trials planned for 2018) and two additional candidates.[1][2] This pivotal funding and acquisition marked key moments, positioning the firm to develop therapies beyond cancer, such as multiple sclerosis.[6]
(Note: Search results distinguish Macrophage Pharma from Macrophage Therapeutics, Inc., a separate US firm with distinct macrophage-targeting steroids and apoptotic agents; this profile focuses on Macrophage Pharma Ltd.[3][5])
Macrophage Pharma rides the immuno-oncology wave, targeting tumor-associated macrophages (TAMs)—key drivers of tumor immunosuppression amid the rise of checkpoint inhibitors and combination therapies in the 2010s.[1][2] Timing aligned with surging interest in tumor microenvironment modulation post-2016, as macrophages emerged as critical for enhancing immunotherapy efficacy across larger patient populations.[1] Favorable market forces include venture capital influx into precision immuno-oncology and unmet needs in "cold" tumors resistant to PD-1/PD-L1 drugs, where ESM™ offers a small-molecule alternative to biologics.[2][6] The company influences the ecosystem by pioneering macrophage reprogramming, potentially enabling combos with existing standards and expanding to autoimmune indications like MS, contributing to a shift toward multi-modal immune activation.[1][6]
Macrophage Pharma's ESM™ platform positions it for milestone progress, likely advancing its p38MAPi into (or beyond) early clinical data post-2018 trials, with pipeline growth into new macrophage targets amid maturing immuno-oncology combos.[1][2] Trends like AI-driven drug design, bispecifics, and macrophage-centric therapies (e.g., CSF1R inhibitors) will shape its path, amplifying ESM™'s selectivity edge in a market projected to exceed $100B by 2030. Its influence may evolve through partnerships or acquisition by big pharma seeking next-gen TME modulators, building on its strong investor foundation to deliver transformative cancer immunotherapies—echoing its origin as a targeted immune activator in an era of precision medicine.[1][2]
Macrophage Pharma has raised $11.0M across 1 funding round. Most recently, it raised $11.0M Series A in January 2017.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2017 | $11.0M Series A | CRT Pioneer Fund | M Ventures (Merck), Aglaia, Novo Seeds |